ArticleMikrochimica acta2026
Multifunctional cardiac tropin I sensing using MWCNTs-COOH/PoPD composites for integrated warning, screening and protection assessment of traditional Chinese medicine-induced cardiotoxicity.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cardiac troponin I (cTnI), the most sensitive and specific biomarker of myocardial injury, enables early detection of subclinical cardiotoxicity. Highly sensitive cTnI testing is therefore crucial for early safety assessment of TCM. This study developed an electrochemical immunosensor for cTnI using a carboxylated multi-walled carbon nanotube/poly(o-phenylenediamine) (MWCNTs-COOH/PoPD) composite sensing membrane. This design leverages the large surface area and high conductivity of MWCNTs-COOH along with PoPD's biocompatibility to enhance electrochemical performance. Antibodies achieved controllable covalent immobilization with preferential orientation via 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide (EDC/NHS) cross-linking, facilitating specific recognition of cTnI. Under optimized conditions, the sensor exhibited excellent linearity across the ranges of 0.2-40 pg/mL and 0.05-50 ng/mL, with detection limits of 0.06 pg/mL and 4.17 pg/mL, respectively, demonstrating high sensitivity, specificity, and stability. Successfully applied to screen cardiotoxic TCM components, the sensor accurately detected cTnI released from cardiomyocytes, enabling precise quantification of toxins such as aconitine. It was also extended to evaluate myocardial protectants such as baicalin and their synergistic detoxification effects. This work establishes an efficient, sensitive platform for early TCM cardiotoxicity warning and toxic substance identification based on cTnI, while also supporting the screening of protective components. It is crucial for safeguarding the clinical safety of TCM and fostering the sustainable development of its industry.
Indexed as
Identifiers
42700271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.